share_log

Reneo Pharmaceuticals | 8-K: Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results

Reneo Pharmaceuticals | 8-K: Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results

Reneo Pharmaceuticals | 8-K：Reneo Pharmicals公布2024年第一季度财务业绩
美股SEC公告 ·  05/07 22:16

Moomoo AI 已提取核心信息

On May 7, 2024, Reneo Pharmaceuticals, Inc. released its financial results for the first quarter ending March 31, 2024, and provided a business update. The company reported a net loss of $8.4 million, or $0.25 per share, a decrease from the $15.1 million, or $0.60 per share, loss in the same period the previous year. Reneo Pharmaceuticals ended the quarter with $82.8 million in cash, cash equivalents, and short-term investments. Research and development expenses decreased to $4.9 million from $11.0 million in the prior year, primarily due to the suspension of development activities for mavodelpar and workforce reductions. General and administrative expenses also decreased to $4.6 million from $5.1 million, attributed to the same cost-saving measures. The company had previously announced in December 2023 that the STRIDE study of mavodelpar did not meet its primary or secondary efficacy endpoints, leading to the suspension of the drug's development and a significant workforce reduction of approximately 90%. Additionally, Reneo Pharmaceuticals has engaged an independent financial advisor to explore potential strategic alternatives.
On May 7, 2024, Reneo Pharmaceuticals, Inc. released its financial results for the first quarter ending March 31, 2024, and provided a business update. The company reported a net loss of $8.4 million, or $0.25 per share, a decrease from the $15.1 million, or $0.60 per share, loss in the same period the previous year. Reneo Pharmaceuticals ended the quarter with $82.8 million in cash, cash equivalents, and short-term investments. Research and development expenses decreased to $4.9 million from $11.0 million in the prior year, primarily due to the suspension of development activities for mavodelpar and workforce reductions. General and administrative expenses also decreased to $4.6 million from $5.1 million, attributed to the same cost-saving measures. The company had previously announced in December 2023 that the STRIDE study of mavodelpar did not meet its primary or secondary efficacy endpoints, leading to the suspension of the drug's development and a significant workforce reduction of approximately 90%. Additionally, Reneo Pharmaceuticals has engaged an independent financial advisor to explore potential strategic alternatives.
2024年5月7日，雷纽制药公司发布了截至2024年3月31日的第一季度财务业绩，并提供了业务更新。公司报告净亏损840万美元，每股亏损0.25美元，与上一年同期每股亏损1510万美元，或每股亏损0.60美元相比有所减少。雷纽制药第一季度末现金、现金等价物和短期投资为8280万美元。研发费用从上一年的1100万美元降至490万美元，主要是由于mavodelpar开发活动暂停和员工裁员。总务和行政支出也从510万美元下降至460万美元，归因于相同的节约成本措施。公司此前在2023年12月宣布，mavodelpar的STRIDE研究未达到主要或次要的疗效终点，导致该药物开发暂停以及约90%的重大员工裁员。此外，雷纽制药已委托独立财务顾问探讨潜在的战略选择。
2024年5月7日，雷纽制药公司发布了截至2024年3月31日的第一季度财务业绩，并提供了业务更新。公司报告净亏损840万美元，每股亏损0.25美元，与上一年同期每股亏损1510万美元，或每股亏损0.60美元相比有所减少。雷纽制药第一季度末现金、现金等价物和短期投资为8280万美元。研发费用从上一年的1100万美元降至490万美元，主要是由于mavodelpar开发活动暂停和员工裁员。总务和行政支出也从510万美元下降至460万美元，归因于相同的节约成本措施。公司此前在2023年12月宣布，mavodelpar的STRIDE研究未达到主要或次要的疗效终点，导致该药物开发暂停以及约90%的重大员工裁员。此外，雷纽制药已委托独立财务顾问探讨潜在的战略选择。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间